TROG 99.05 - Lung Tumour Volume - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

Tumour Volume as an Independent Prognosis Factor in Patients with Non-Small Cell Lung Cancer: A Protocol for a Progressive Database

Primary Sponsor

Clinical Trial Registration

Registration Link

SOCRATES HCC trial - all Australian sites open

5 March, 2025

All Australian sites open for SOCRATES HCC trial

5 March 2025: TRIAL UPDATE We’re excited to have

4 March, 2025

TRIAL IN FOCUS: DCIS delivers valuable evidence

4 March 2025: A decade on from the last

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Tumour Volume as an Independent Prognosis Factor in Patients with Non-Small Cell Lung Cancer: A Protocol for a Progressive Database

TROG 99.06 – Bladder (Phase II)

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

Related Post

All Australian sites open for SOCRATES HCC trial

TRIAL IN FOCUS: DCIS delivers valuable evidence

TROG 99.05 – Lung Tumour Volume

Tumour Volume as an Independent Prognosis Factor in Patients with Non-Small Cell Lung Cancer: A Protocol for a Progressive Database

TROG 99.06 – Bladder (Phase II)

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

Related Post

All Australian sites open for SOCRATES HCC trial

TRIAL IN FOCUS: DCIS delivers valuable evidence